Ovarian CanceRx Leadership

Beth Y. Karlan, MD

Director, Cancer Population Genetics
UCLA, Jonsson Comprehensive Cancer Center

Chair, Steering Committee

Ursula A. Matulonis, MD

Chief, Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School

Chair, Arm Selection Committee

Lynda D. Roman, MD

Associate Professor of Obstetrics and Gynecology
Division Chief, Gynecologic Oncology
Keck School of Medicine of USC

Chair, Clinical Leadership

Anil K. Sood, MD

Professor and Vice-Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology
The University of Texas MD Anderson Cancer Center

Chair, Translational Leadership

Andrew W. Lo, PhD

Charles E. and Susan T. Harris Professor, Finance
Director, Laboratory for Financial Engineering
MIT Sloan School of Management

Chair, Financial Innovation and Strategy

Kathleen Moore, MD, MS

Professor of Gynecologic Oncology, Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center

Co-Chair, Arm Selection Committee

Kunle Odunsi, MD, PhD

Director, Comprehensive Cancer Center
Biological Sciences Division Dean for Oncology
University of Chicago Medicine

Co-Chair, Translational Leadership


Ovarian cancer accounts for 5% of all cancer death in women


Cases detected early have a +90% survival rate after 5 years


Women with BRCA1 gene mutation have a 45% lifetime risk of ovarian cancer

Ovarian CanceRx

Rapid. Adaptive. Needed.

In the Fight Against Advanced Ovarian Cancer.